文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗

治疗计划中采用特定十二指肠剂量限值可降低宫颈癌根治性腹主动脉旁放疗后的毒性

Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer.
PubMed 文献 · Pract Radiat Oncol · 2021-12-25

本研究验证宫颈癌腹主动脉旁淋巴结放疗时十二指肠剂量限制为V55<15 cm³和V60<2 cm³的安全性,97例患者接受至少56 Gy照射,仅1例出现3级十二指肠毒性,结论认为该限值可行并能减少十二指肠毒性且维持可接受的局部控制率。

要点

  • 97例宫颈癌腹主动脉旁淋巴结放疗患者中,十二指肠V55中位3.5 cm³,V60中位0.3 cm³。
  • 仅1例出现3级十二指肠毒性(狭窄需内镜下球囊扩张),且狭窄位于高剂量boost体积外。
  • 6例(6%)出现腹主动脉旁区域首次复发。

核心结论

  • 对宫颈癌伴腹主动脉旁淋巴结受累患者,将十二指肠剂量限制为V55<15 cm³和V60<2 cm³是可行的,可减少十二指肠毒性并维持可接受的局部控制率。

研究设计与样本

  • 2010年至2018年间接受放疗的97例宫颈癌患者,腹主动脉旁大体受累淋巴结接受至少56 Gy照射。
  • 88例(91%)接受同步放化疗,90例(93%)对初始腹主动脉旁野接受调强放疗,95例(98%)对序贯腹主动脉旁推量接受调强放疗。
  • V55<15 cm³和V60<2 cm³标准于2014年实施。
  • 66例(68%)在约20次分次后行重新模拟扫描;复合十二指肠剂量基于初始CT扫描计算50例(52%),基于重新模拟CT扫描计算47例(48%)。

主要发现

  • 十二指肠V55中位值为3.5 cm³(四分位距[IQR],0.2-8.1 cm³),V60中位值为0.3 cm³(IQR,0.0-1.8)。
  • 18例患者超出限值,其中16例(89%)在2014年前治疗;2014年后治疗的2例因显著体重减轻和前后径减小,复合计划可能高估了真实剂量。
  • 仅1例出现3级十二指肠毒性(治疗后3个月狭窄需内镜下球囊扩张),但狭窄位于高剂量推量体积外,且患者有胃炎病史。
  • 6例(6%)出现腹主动脉旁区域首次复发。

关键数值与推荐

  • 十二指肠剂量限值:V55<15 cm³和V60<2 cm³。
  • 腹主动脉旁大体受累淋巴结接受至少56 Gy照射。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to validate the safety of paraaortic nodal (PAN) radiation therapy (RT) for patients with cervical cancer when the duodenal dose is limited to V55 < 15 cm3 and V60 < 2 cm3. METHODS AND MATERIALS: A total of 97 patients who were treated with RT for cervical cancer between 2010 and 2018 received at least 56 Gy to grossly involved PANs. Patients were treated with concurrent chemoradiation (n = 88; 91%), with 93% of patients (n = 90) receiving intensity modulated RT to the initial PAN field and 98% (n = 95) receiving intensity modulated RT to a sequential PAN boost. The V55 < 15 cm3 and V60 <2 cm3 criteria were implemented in 2014. Normal tissues were contoured on computed tomography (CT) simulation data sets, and the duodenum was contoured from the gastric outlet to the duodenojejunal flexure. Sixty-six patients (68%) had a resimulation scan after approximately 20 fractions. Composite duodenal doses were calculated using the initial CT scan for 50 patients (52%) and the resimulation CT scan for 47 patients (48%) depending on the anatomic changes throughout treatment. RESULTS: The median duodenal V55 was 3.5 cm3 (interquartile range [IQR], 0.2-8.1 cm3) and the median V60 was 0.3 cm3 (IQR, 0.0-1.8). Constraints were exceeded in 18 patients, of whom 16 patients (89%) had been treated before 2014. Treatment for the 2 patients treated after 2014 was complicated by significant weight loss and reduced anterior-posterior diameter, which likely overestimated the true dose on the composite plan. Only 1 patient experienced grade 3 duodenal toxicity (stricture requiring endoscopic balloon dilation 3 months after treatment); however, the stricture was outside of the high-dose boost volume, and the patient had a history of gastritis. Six patients (6%) had a first recurrence within the PAN region. CONCLUSIONS: Limiting the duodenal dose to V55 < 15 cm3 and V60 < 2 cm3 for patients with cervical cancer and PAN involvement is feasible, and minimizes duodenal toxicity while maintaining acceptable local control rates.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lakomy DS, Wu J, Chapman BV, et al. Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer. Pract Radiat Oncol. 2021. PMID: 34958984. doi:10.1016/j.prro.2021.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。